BLISS GVS PHARMA
|
The Current P/E Ratio of BLISS GVS PHARMA is 23.94.
Share Price | ₹163.6 | Dec 03,2024 |
Market Cap | ₹1,722.7 Cr | |
Earnings-TTM | ₹72.0 Cr | TTM-Consolidated Results |
Price/Earnings | 23.94x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of BLISS GVS PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,722.7 Cr] as on Dec 03,2024
(/) Earnings [ ₹72.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 23.94x ]
Thus, for BLISS GVS PHARMA , the investors are currently willing to pay 23.94 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BLISS GVS PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of BLISS GVS PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of BLISS GVS PHARMA
PE Ratio Performance Analysis for BLISS GVS PHARMA
- BLISS GVS PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 20.94x.
- BLISS GVS PHARMA 's operated at median p/e ratio of 14.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, BLISS GVS PHARMA 's p/e ratio peaked in Mar2022 at 53.04x.
- BLISS GVS PHARMA 's p/e ratio hit its five-year low in Mar2023 of 10.47x.
How does BLISS GVS PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
BLISS GVS PHARMA | 71.96 | 23.94 | 1,722.7 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 38.75 | 431,544.0 |
CIPLA LTD | 4,485.22 | 27.63 | 123,920.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 18.91 | 102,224.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 22.99 | 98,832.3 |
DIVIS LABORATORIES LTD | 1,836.00 | 89.80 | 164,865.0 |
MANKIND PHARMA LTD | 2,124.86 | 48.25 | 102,527.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 63.14 | 113,772.0 |
LUPIN LTD | 2,651.94 | 35.81 | 94,953.0 |
AUROBINDO PHARMA LTD | 3,598.83 | 20.44 | 73,544.0 |
ABBOTT INDIA LTD | 1,284.66 | 47.05 | 60,440.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BLISS GVS PHARMA 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.91x |
Max industry PE | 89.80x |
Median industry PE | 35.81x |
Average industry PE | 39.70x |
You may also like the below Video Courses